Compared to conventional immunosuppressive treatments including glucocorticoids, Ld-IL2 therapy potentially possesses a highly sought-after advantage–reinstate immune tolerance without imposing immunosuppression, therefore alleviating the significant risk of infection in patients with autoimmune diseases. The gene discussed is IL2; the disease is autoimmune disease.